🟢 Anixa Biosciences is trading 7.34% up in pre-market ahead of September 9 clinical-program presentation

Anixa Biosciences is trading 7.34% up now at $3.11 after announcing a September 9 presentation at the Nasdaq & LD Micro Inaugural SF Summit.

• Management is expected to provide updates on its ovarian-cancer CAR-T therapy and breast-cancer vaccine programs.
• The scheduled investor event is the clearest company-specific catalyst identified; no new earnings release or definitive clinical announcement was found before the pre-market session.
• Major U.S. futures are lower, while elevated oil prices and bond yields are pressuring risk assets; the presentation appears more relevant to the move.